脑淀粉样血管病发病机制的研究进展

doi:10.3969/j.issn.1673-5765.2021.12.014

摘要/Abstract

摘要： 脑淀粉样血管病（cerebral amyloid angiopathy，CAA）的主要致病物质是β淀粉样蛋白，其产生异常、清除障碍导致异常沉积，引起管壁破坏、管腔狭窄等病理变化，最终导致CAA。目前CAA的具体发病机制尚不清楚，涉及的成分复杂。本文介绍了β淀粉样蛋白产生及清除的三种过程及其平衡破坏的后续效应和主要影响因素，同时从病因分类的角度阐明CAA的类型。

文章导读： 脑淀粉样血管病由β淀粉样蛋白产生及清除的动态平衡被破坏导致，致病途径尚不清楚，探讨其发病机制有助于寻找治疗靶点。

关键词: 脑淀粉样血管病; β淀粉样蛋白; 机制; 病理生理; 基因

Abstract: Amyloid β (Aβ) is the main pathogenic substance of cerebral amyloid angiopathy (CAA). The disorders of Aβ production and clearance results in abnormal Aβ deposits, and causes a series of pathological changes such as vascular wall destruction and lumen stenosis, which ultimately leads to CAA. At present, the specific pathogenic mechanism of CAA is still unclear, and the involved components are complex. This article introduced the three pathways of Aβ production and elimination, the subsequent effects after this balance being disrupted and the main influencing factors, and the CAA classification from etiological perspective.

Key words: Cerebral amyloid angiopathy; Amyloid β; Mechanism; Pathophysiology; Gene

吴娟娟, 倪俊. 脑淀粉样血管病发病机制的研究进展[J]. 中国卒中杂志, 2021, 16(12): 1278-1283.

WU Juanjuan, NI Jun. Advances in the Mechanism of Cerebral Amyloid Angiopathy[J]. Chinese Journal of Stroke, 2021, 16(12): 1278-1283.

参考文献

[1] JAUNMUKTANE Z，QUAEGEBEUR A，TAIPA
R，et al. Evidence of amyloid-β cerebral amyloid
angiopathy transmission through neurosurgery[J].
Acta Neuropathol，2018，135（5）：671-679.
[2] EISENBERG D，JUCKER M. The amyloid state of
proteins in human diseases[J]. Cell，2012，148（6）：
1188-1203.
[3] BENSON M D，BUXBAUM J N，EISENBERG D
S，et al. Amyloid nomenclature 2020：update and
recommendations by the International Society of
Amyloidosis（ISA）nomenclature committee[J].
Amyloid，2020，27（4）：217-222.
[4] HERVAS R，RAU M J，PARK Y，et al. Cryo-
EM structure of a neuronal functional amyloid
implicated in memory persistence in Drosophila[J].
Science，2020，367（6483）：1230-1234.
[5] YAMADA M. Cerebral amyloid angiopathy：
emerging concepts[J]. J Stroke，2015，17（1）：17-30.
[6] SHARMA R，DEARAUGO S，INFELD B，et al.
Cerebral amyloid angiopathy：review of clinicoradiological
features and mimics[J]. J Med Imaging
Radiat Oncol，2018，62（4）：451-463.
[7] ATTEMS J，JELLINGER K A，LINTNER F.
Alzheimer's disease pathology influences severity
and topographical distribution of cerebral amyloid
angiopathy[J]. Acta Neuropathol，2005，110（3）：
222-231.
[8] GREENBERG S M，CHARIDIMOU A. Diagnosis
of cerebral amyloid angiopathy：evolution of the
Boston criteria[J]. Stroke，2018，49（2）：491-497.
[9] PANZA F，LOZUPONE M，SOLFRIZZI V，et al.
BACE inhibitors in clinical development for the
treatment of Alzheimer's disease[J]. Expert Rev
Neurother，2018，18（11）：847-857.
[10] MENDEL T A，WIERZBA-BOBROWICZ T，
LEWANDOWSKA E，et al. The development of
cerebral amyloid angiopathy in cerebral vessels.
A review with illustrations based upon own
investigated post mortem cases[J]. Pol J Pathol，2013，
64（4）：260-267.
[11] GIREUD-GOSS M，MACK A F，MCCULLOUGH
L D，et al. Cerebral amyloid angiopathy and bloodbrain
barrier dysfunction[J]. Neuroscientist，2021，27
（6）：668-684.
[12] MATSUOKA Y，SAITO M，LAFRANCOIS J，et
al. Novel therapeutic approach for the treatment of
Alzheimer's disease by peripheral administration of
agents with an affinity to beta-amyloid[J]. J Neurosci，
2003，23（1）：29-33.
[13] KALARIA R N，PREMKUMAR D R，PAX A B，et
al. Production and increased detection of amyloid
beta protein and amyloidogenic fragments in brain
microvessels，meningeal vessels and choroid plexus
in Alzheimer's disease[J]. Brain Res Mol Brain Res，
1996，35（1/2）：58-68.
[14] TARASOFF-CONWAY J M，CARARE R O，
OSORIO R S，et al. Clearance systems in the brainimplications
for Alzheimer disease[J]. Nat Rev
Neurol，2015，11（8）：457-470.
[15] GREENBERG S M，BACSKAI B J，
HERNANDEZ-GUILLAMON M，et al. Cerebral
amyloid angiopathy and Alzheimer disease-one
peptide，two pathways[J]. Nat Rev Neurol，2020，16
（1）：30-42.
[16] ALBARGOTHY N J，JOHNSTON D A，
MACGREGOR-SHARP M，et al. Convective influx/
glymphatic system：tracers injected into the CSF
enter and leave the brain along separate periarterial
basement membrane pathways[J]. Acta Neuropathol，
2018，136（1）：139-152.
[17] MESTRE H，TITHOF J，DU T，et al. Flow of
cerebrospinal fluid is driven by arterial pulsations
and is reduced in hypertension[J]. Nat Commun，
2018，9（1）：4878.
[18] ALDEA R，WELLER R O，WILCOCK D M，et al.
Cerebrovascular smooth muscle cells as the drivers
of intramural periarterial drainage of the brain[J/OL].
Front Aging Neurosci，2019，11：1[2021-10-02].
https：//doi.org/10.3389/fnagi.2019.00001.
[19] VAN VELUW S J，HOU S S，CALVORODRIGUEZ
M，et al. Vasomotion as a driving
force for paravascular clearance in the awake mouse
brain[J/OL]. Neuron，2020，105（3）：549-561，
e5[2021-10-02]. https：//doi.org/10.1016/j.neuron.

2019.10.033.

[20] SMITH A J，YAO X，DIX J A，et al. Test of the
'glymphatic' hypothesis demonstrates diffusive
and aquaporin-4-independent solute transport
in rodent brain parenchyma[J/OL]. Elife，2017，
6：e27679[2021-10-02]. https：//doi.org/10.7554/
eLife.27679.001.
[21] YAMAGUCHI H，YAMAZAKI T，LEMERE C A，
et al. Beta amyloid is focally deposited within the
outer basement membrane in the amyloid angiopathy
of Alzheimer's disease. An immunoelectron
microscopic study[J]. Am J Pathol，1992，141（1）：
249-259.
[22] DAWKINS E，SMALL D H. Insights into the
physiological function of the β-amyloid precursor
protein：beyond Alzheimer's disease[J]. J Neurochem，
2014，129（5）：756-769.
[23] DEANE R，SAGARE A，HAMM K，et al. ApoE
isoform-specific disruption of amyloid beta peptide
clearance from mouse brain[J]. J Clin Invest，2008，
118（12）：4002-4013.
[24] GATTI L，TINELLI F，SCELZO E，et al.
Understanding the pathophysiology of cerebral
amyloid angiopathy[J]. Int J Mol Sci，2020，21（10）：
3435.
[25] ONO K，TSUJI M. Protofibrils of amyloid-β are
important targets of a disease-modifying approach
for Alzheimer's disease[J]. Int J Mol Sci，2020，21
（3）：952.
[26] VAN VELUW S J，SHIH A Y，SMITH E E，et al.
Detection，risk factors，and functional consequences
of cerebral microinfarcts[J]. Lancet Neurol，2017，16
（9）：730-740.
[27] BUGIANI O，GIACCONE G，ROSSI G，et al.
Hereditary cerebral hemorrhage with amyloidosis
associated with the E693K mutation of APP[J]. Arch
Neurol，2010，67（8）：987-995.
[28] CARMONA-IRAGUI M，VIDELA L，LLEÓ A，
et al. Down syndrome，Alzheimer disease，and
cerebral amyloid angiopathy：the complex triangle
of brain amyloidosis[J]. Dev Neurobiol，2019，79（7）：
716-737.
[29] LIU Y，YU J T，WANG H F，et al. APOE genotype
and neuroimaging markers of Alzheimer's disease：
systematic review and meta-analysis[J]. J Neurol
Neurosurg Psychiatry，2015，86（2）：127-134.
[30] HOWE M D，MCCULLOUGH L D，URAYAMA
A. The role of basement membranes in cerebral
amyloid angiopathy[J/OL]. Front Physiol，2020，
11：601320[2021-10-02]. https：//doi.org/10.3389/
fphys.2020.601320.
[31] ARIMA H，TZOURIO C，ANDERSON C，et
al. Effects of perindopril-based lowering of blood
pressure on intracerebral hemorrhage related to
amyloid angiopathy：the PROGRESS trial[J]. Stroke，
2010，41（2）：394-396.
[32] BONDA D J，MANJILA S，MEHNDIRATTA P，et
al. Human prion diseases：surgical lessons learned
from iatrogenic prion transmission[J/OL]. Neurosurg
Focus，2016，41（1）：E10[2021-10-02]. https：//doi.
org/10.3171/2016.5.FOCUS15126.